ReviewActa pharmacologica Sinica2026
Nanobody-based targeted cancer therapy and immunotherapy: fear not the future.
Review in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in understanding tumor heterogeneity and the tumor microenvironment (TME) have ushered in a new era of targeted and immunotherapy. Both targeted and immunotherapy mainly rely on the use of specific antibodies against the tumor targets. Although monoclonal antibodies (mAbs) have achieved tremendous success, the full potential of these full-size antibodies is hampered by the large size, low tumor permeability, and uneven biodistribution, which will obstruct the clinical treatment outcome. Nanobodies (Nbs), derived from camelid heavy-chain antibodies, offer a revolutionary alternative due to their unique structural and functional properties. This review highlights the beneficial characteristics of Nbs, notably their ability to access hidden epitopes and penetrate dense TME, along with a favorable immunogenic profile. Their therapeutic applications in cancer are explored across multiple fronts: from monovalent and multivalent constructs targeting receptor tyrosine kinases and other cancer-related molecules to serving as delivery vehicles for drugs, radionuclides, and photosensitizers. In immunotherapy, Nbs play a pivotal role by activating immune cells, blocking immune checkpoints, and enhancing adoptive cell therapies. Despite challenges like rapid renal clearance, engineering and humanization strategies are advancing Nbs toward improved efficacy and safety in oncology. This review provides a comprehensive overview of current Nb-based therapies, their mechanisms, and future directions in oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.